Relmada Therapeutics Announces Q1 2025 Financial Call Plans

Author: Evelyn Baker Updated: 05-08-2025 07:35 AM

Relmada Therapeutics to Host Financial Results Conference Call

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering clinical-stage biotechnology company, is prepared to discuss its financial results for the first quarter concluded on March 31, 2025. This important conference call and webcast is scheduled for a convenient time on Monday, May 12, 2025, at 4:30 PM ET. Participants are encouraged to join and learn about the company's progress and financial developments.

Key Details for the Upcoming Call

This conference call presents an opportunity for stakeholders to gain insights into Relmada's financial performance and future strategies. Interested participants can join the call by using the following dial-in numbers. For those in the U.S., the number is 1-877-407-0792, while international participants can dial 1-201-689-8263. The conference ID to access the call is 13753596. The company has also arranged for a webcast, accessible online, so that anyone can tune in from the comfort of their homes or offices.

Webcast Access and Replay Information

The webcast will provide a comprehensive overview of the financial results as well as recent advancements made by Relmada. A replay of the webcast will be made available shortly after the live event, ensuring that those unable to attend can still access the content. This replay will be found in the Investors section on the Relmada website.

About Relmada Therapeutics, Inc.

Founded with a vision of transforming the treatment landscape, Relmada Therapeutics is intensely focused on developing innovative breakthrough therapies aimed at enhancing the quality of life for patients suffering from serious conditions. One of its flagship investigational treatments, NDV-01, is currently undergoing evaluation in a Phase 2 study specifically targeted at High-Grade Non-Muscle Invasive Bladder Cancer. In tandem, the company is preparing to advance another significant therapy, sepranolone. This product is poised for Phase 2b studies focusing on compulsion-related disorders, which include Tourette’s Syndrome and Prader-Willi Syndrome, promising hope to those affected.

Investor and Media Contacts

If you have inquiries regarding investor relations or media coverage, you are encouraged to reach out to Brian Ritchie at LifeSci Advisors for investment-related matters. For media inquiries, the Corporate Communications team is available for assistance. Contact information for both can be found on the Relmada website.

Frequently Asked Questions

What will be discussed during the conference call?

The call will focus on the financial results for the first quarter of 2025 and the company's recent business advancements.

How can I access the conference call?

You can join the call by dialing 1-877-407-0792 for US participants or 1-201-689-8263 for international attendees.

Is there a way to listen to the call after it has finished?

Yes, a replay of the webcast will be available in the Investors section of the Relmada website shortly after the event concludes.

What is the primary focus of Relmada Therapeutics?

Relmada focuses on developing innovative therapeutic solutions to address serious health issues affecting targeted patient populations.

What are NDV-01 and sepranolone?

NDV-01 is an investigational treatment in a Phase 2 study for bladder cancer, while sepranolone is aimed at treating compulsion-related disorders and is ready to progress to Phase 2b trials.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.